Abstract: Androgen-ablation therapy is the primary treatment for prostate cancer that has escaped local control through surgical excision or radiation (hormone sensitive, HS). While generally effective, the treatment is short-lived and hormone refractory (HR) cancer eventually develops. To identify the responsible mechanisms, we set out a microarray experiment using seven pairs of HS and HR xenografts and identified androgen receptor (AR) overexpression is the only consistent change in the progression of prostate cancer. In the last grand period, I confirmed by western blot analysis that androgen receptor protein is higher in HR than HS tumors. Through lentivirus and retrovirus systems, I was able to overexpress AR in both LNCaP and LAPC4 cells. In vitro and in vivo experiments demonstrated that overexpression of AR is sufficient for HS-to-HR transition. We are testing if AR is necessary for the growth of androgen independent prostate cancer
| Limitations: |
 APPROVED FOR PUBLIC RELEASE |
| Description: |
Annual summary rept. 15 Dec 2001-14 Dec 2002 |
| Pages: |
8 |
| Report Date: |
JAN 2003 |
| Contract Number: |
DAMD17-02-1-0024 |
| Report Number: |
A515714 |
|
|
|
|
Keywords relating to this report:
